Recruiting PHASE1 INTERVENTIONAL 1-arm NCT07194044

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (METTSEO)

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Interventions Actinomycin Cabozantinib Cyclophosphamide Doxorubicin Etoposide Ifosfamide Irinotecan Liposomal doxorubicin Temozolomide Topotecan Vincristine

Updated 4 times since 2025 Last updated: Jan 27, 2026 Started: Feb 28, 2026 Primary completion: Oct 31, 2030 Completion: Oct 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07194044, this PHASE1 trial focuses on Metastatic Ewing Sarcoma and remains actively recruiting participants. Sponsored by H. Lee Moffitt Cancer Center and Research Institute, it has been updated 4 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1
Nov 2025 — Jan 2026 [monthly]

Recruiting PHASE1
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lee Moffitt Cancer Center and Research Institute
National Pediatric Cancer Foundation

Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Buffalo, United States , Chapel Hill, United States , Charlotte, United States , Cleveland, United States , Columbus, United States , Gainesville, United States , Grand Rapids, United States , Hartford, United States , Jacksonville, United States and 7 more locations